DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Phase 3

Recruiting

Conditions: Thyroid Eye Disease

Interventions: Other: Placebo
Biological: Teprotumumab

First Posted Date: 2024-02-08

Last Posted Date: 2025-05-08

Lead Sponsor: Amgen

Target Recruit Count: 80

Registration Number: NCT06248619

Locations: 🇺🇸
Catalina Eye Care - NVISION - PPDS, Tucson, Arizona, United States
🇺🇸
Shiley Eye Center University of California at San Diego, La Jolla, California, United States
🇺🇸
Amy Patel Jain MD Inc., Newport Beach, California, United States

and more 49 locations

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Phase 3

Recruiting

Conditions: Sjögren's Syndrome (SS)

Interventions: Drug: Dazodalibep
Drug: Placebo

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 435

Registration Number: NCT06245408

Locations: 🇯🇵
Chubu Rosai Hospital, Nagoya-Shi, Aiti, Japan
🇮🇹
A.O.U. Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy
🇮🇹
Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy

and more 196 locations

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Phase 4

Active, not recruiting

Conditions: Gout

Interventions: Biological: Pegloticase
Drug: Methotrexate

First Posted Date: 2024-01-29

Last Posted Date: 2025-02-20

Lead Sponsor: Amgen

Target Recruit Count: 262

Registration Number: NCT06229145

Locations: 🇺🇸
The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸
Orthopedic Physicians Alaska - Rheumatology and Infusion, Anchorage, Alaska, United States
🇺🇸
Arizona Arthritis and Rheumatology, Tucson, Arizona, United States

and more 66 locations

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD

Phase 3

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

First Posted Date: 2024-01-25

Last Posted Date: 2025-05-02

Lead Sponsor: Amgen

Target Recruit Count: 151

Registration Number: NCT06224192

Locations: 🇺🇸
Kern Research Inc, Bakersfield, California, United States
🇺🇸
Long Beach Research Institute, Long Beach, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States

and more 44 locations

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Rocatinlimab

First Posted Date: 2024-01-19

Last Posted Date: 2024-11-19

Lead Sponsor: Amgen

Target Recruit Count: 20

Registration Number: NCT06214481

Locations: 🇨🇳
Huashan Hospital Affiliated to Fudan University?, Shanghai, China

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Phase 3

Recruiting

Conditions: Extensive-Stage Small-Cell Lung Cancer
Small-Cell Lung Cancer

Interventions: Drug: Tarlatamab
Drug: Durvalumab

First Posted Date: 2024-01-18

Last Posted Date: 2025-05-14

Lead Sponsor: Amgen

Target Recruit Count: 550

Registration Number: NCT06211036

Locations: 🇩🇰
Odense Universitetshospital, Odense C, Denmark
🇰🇷
Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of
🇨🇳
Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China

and more 215 locations

Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Avacopan
Drug: Simvastatin

First Posted Date: 2024-01-17

Last Posted Date: 2024-01-17

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT06207682

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase 4

Recruiting

Conditions: Neuromyelitis Optica Spectrum Disorder

Interventions: Other: Blood tests
Drug: Inebilizumab

First Posted Date: 2023-12-22

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 30

Registration Number: NCT06180278

Locations: 🇵🇱
Uniwersyteckie Centrum Kliniczne WUM, Warszawa, Mazowieckie, Poland
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇭🇺
Szegedi Tudományegyetem, ÁOK, Szent-Györgyi Albert Klinikai Központ, Szeged, Csongrád, Hungary

and more 16 locations

Aimovig Pregnancy Exposure Registry

Recruiting

Conditions: Migraine

Interventions: Drug: erenumab-aooe

First Posted Date: 2023-11-29

Last Posted Date: 2024-10-03

Lead Sponsor: Amgen

Target Recruit Count: 2842

Registration Number: NCT06150781

Locations: 🇺🇸
IQVIA Virtual Site, Durham, North Carolina, United States

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Phase 3

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: apremilast
Drug: Placebo

First Posted Date: 2023-11-08

Last Posted Date: 2025-03-13

Lead Sponsor: Amgen

Target Recruit Count: 203

Registration Number: NCT06122649

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy